Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency

NCT ID: NCT05571748

Last Updated: 2023-01-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-28

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effects of alpha-lipoic acid supplementation on redox status, physiological and biochemical parameters in diabetic individuals with G6PD deficiency, after acute exercise.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a randomized double-blind, crossover design, a total of forty people will participate in the research voluntarily: (a) ten people with G6PD (Mediterranean type) enzyme deficiency), (b) ten people with G6PD (Mediterranean type) enzyme deficiency and a disorder of carbohydrate metabolism (diabetes, prediabetes), (c) ten people with a disorder of carbohydrate metabolism (diabetes mellitus and prediabetes) and, (d) ten people without any health problem (control group). They will be supplemented with either 600 mg of alpha-lipoic acid (experimental condition) or placebo (control condition) every day for 4 weeks, separated by a 4-week washout period. All participants will be randomly assigned to both conditions.

Before intervention, all participants will be informed about the study protocol, fill a medical history questionnaire and sign an informed consent form. Moreover, measurements of anthropometric characteristics and physiological parameters, as well as a VO2peak test will be performed.

Participants will perform a trial of exercise (70% VO2peak for 45min and 90% till exhaustion) before and after each condition (i.e. a total of 4 trials). Blood samples will be collected before, immediately after and 1 hour after each exercise trial. Moreover, measurements of anthropometric characteristics, physiological and psychological parameters will be performed before and after each condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

G6PD Deficiency Carbohydrate Metabolism Disorder Oxidative Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

G6PD deficiency (only) - Intervention

Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 G6PD deficient individuals.

Group Type EXPERIMENTAL

Alpha-lipoic acid

Intervention Type DIETARY_SUPPLEMENT

A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.

G6PD deficiency (only) - Placebo

Placebo administration for 4 weeks in a counterbalanced manner to 120 G6PD deficient individuals.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

A trial of acute exercise before and after 4 weeks of placebo supplementation.

G6PD deficiency and CHO metabolism disorder - Intervention

Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.

Group Type EXPERIMENTAL

Alpha-lipoic acid

Intervention Type DIETARY_SUPPLEMENT

A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.

G6PD deficiency and CHO metabolism disorder - Placebo

Placebo for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

A trial of acute exercise before and after 4 weeks of placebo supplementation.

CHO metabolism disorder (only) - Intervention

Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.

Group Type EXPERIMENTAL

Alpha-lipoic acid

Intervention Type DIETARY_SUPPLEMENT

A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.

CHO metabolism disorder (only) - Placebo

Placebo for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

A trial of acute exercise before and after 4 weeks of placebo supplementation.

Controls - Intervention

Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.

Group Type EXPERIMENTAL

Alpha-lipoic acid

Intervention Type DIETARY_SUPPLEMENT

A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.

Controls - Placebo

Placebo for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

A trial of acute exercise before and after 4 weeks of placebo supplementation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alpha-lipoic acid

A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.

Intervention Type DIETARY_SUPPLEMENT

Placebo

A trial of acute exercise before and after 4 weeks of placebo supplementation.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Physical exercise Physical exercise

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with normal G6PD activity
* Individuals with G6PD deficiency
* Individuals with CHO metabolism disorders (diabetes, prediabetes)
* Individuals with G6PD deficiency and CHO metabolism disorders (diabetes, prediabetes)

Exclusion Criteria

* Health problems that contraindicate participation to exercise
* Should not take any medication that affects the body's antioxidant mechanisms as well as dietary supplements containing antioxidants
* Women during lactation or gestation
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Thessaly

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Athanasios Z. Jamurtas

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Athanasios Z Jamurtas, PhD

Role: STUDY_DIRECTOR

University of Thessaly

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Athanasios Z Jamurtas, PhD

Role: CONTACT

2431047054 ext. +30

Athanasios Gatsas, MSc

Role: CONTACT

6971559250 ext. +30

References

Explore related publications, articles, or registry entries linked to this study.

Georgakouli K, Deli CK, Zalavras A, Fatouros IG, Kouretas D, Koutedakis Y, Jamurtas AZ. Alpha-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency. Food Chem Toxicol. 2013 Nov;61:69-73. doi: 10.1016/j.fct.2013.01.055. Epub 2013 Feb 14.

Reference Type BACKGROUND
PMID: 23416142 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

G6PD_Diabetes

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lepticore in Metabolic Syndrome and Weight Loss
NCT01046968 COMPLETED PHASE1/PHASE2